NEW YORK (GenomeWeb News) – The Van Andel Institute plans to become a hub of epigenetics research by developing a consortium of four US academic institutions and one from abroad that will collaborate to develop new personalized epigenetic treatments.

The initiative will be led by Peter Jones, director of research and chief scientific officer at the Van Andel Research Institute, which is based at VAI's headquarters in Grand Rapids, Mich. He already is working with international research partners on epigenetic therapies to treat cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.